Sponsored Links
| Shire Announces European Approval Of VPRIV(R) (velaglucerase Alfa) For The Treatment Of Type 1 Gaucher Disease |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |||
|
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease... Read more: Lymphology/Lymphedema News From Medical News Today
|